MOA icon

Unique multitargeted MOA

Discover how RYBREVANT® +
LAZCLUZE™ work

Explore more
Lungs

Clinical experience in first line

Efficacy and safety profile of RYBREVANT® + LAZCLUZE™

See the results
Clipboard with writing

Resources for you and your practice

Support your patients throughout their treatment journey

Learn more

CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; mNSCLC, metastatic non–small cell lung cancer; MOA, mechanism of action; mPFS, median progression-free survival; NSCLC, non–small cell lung cancer; PFS, progression-free survival.

References:

  1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. Press release. Johnson & Johnson. August 20, 2024. Accessed August 20, 2024.
    https://www.prnewswire.com/news-releases/rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-approved-in-the-us-as-a-first-line-chemotherapy-free-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer-302226047.html